CytoDyn (CYDY) Tax Provisions (2018 - 2019)

CytoDyn's (CYDY) quarterly Tax Provisions came in at -$81.0 in Q2 2019, up 100.0% on a QoQ basis from -$2.8 million in Q4 2018.

CytoDyn (CYDY) Tax Provisions (2018 - 2019) Analysis & Trends

CytoDyn (CYDY) has 2 years of Tax Provisions data on file, last reported at -$81.0 in Q2 2019.

Quarterly Tax Provisions changed N/A year-over-year to -$81.0 in Q2 2019, while the trailing twelve-month figure through Feb 2020 was -$81.0 (up 100.0% YoY) and the FY2019 annual result came in at -$2.8 million, changed N/A from the prior year.
Tax Provisions advanced to -$81.0 in Q2 2019, from -$2.8 million in the prior quarter.
In the past five years, Tax Provisions ranged from a high of -$81.0 in Q2 2019 to a low of -$2.8 million in Q4 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	59.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	75.45 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	267.73
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.31 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.90 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-	-

Historic Data

Download Data

Date	Value
May 31, 2019	-81.00
Nov 30, 2018	-2.83 Mn